Next, to evaluate the anti-tumor activity of CBD in vivo, both immunocompetent and immunocompromised syngeneic mice models (wild-type C57BL/6J mice, athymic nude mice, and Rag1 KO mice) were used. The gene discussed is RAG1; the disease is neoplasm.